Bitesized Briefing is returning for March!
Our wonderful speakers this month include Ms. Karen McGowan, ANP Gynaecology and Mr. Damien McGowan, Porter St. Lukes NPRO / Beaumont Hospital (no relation!)
Karen will provide some .
All staff are welcome and we hope to see you in the Richard Carmichael Lecture Theatre at 12.30 on the 24th April. Refreshments available afterwards.
Beaumont Hospital has been approved by the National Cancer Control Programme (NCCP) as a centre for the delivery of cellular therapies for the management of haematological malignancies in adult patients, marking an important step in expanding specialised cancer treatment services.
Cellular therapies, such as CAR T-cells, have the ability to direct immune cells to kill tumour cells within patients. These innovative therapies have produced unprecedented increases in survival and cures in various cancers, particularly for lymphoma and multiple myeloma. New cellular therapies are also in development for solid tumours, brain tumours and non-cancerous conditions, therefore the development of this expertise within the north east region is a hugely positive development for all patients.
The initiative is led by Consultant Haematologists at Beaumont RCSI Cancer Centre, Professor Siobhan Glavey and Professor John Quinn.
Commenting on the announcement, Professor Siobhan Glavey, Beaumont RCSI Cancer Centre, said: “The development of a cellular therapy programme at Beaumont RCSI Cancer Centre is positive news for our cancer patients who will benefit from the most advanced forms of cancer treatment. This new programme builds on our current expertise in cancer and will lead to the development of innovative research in this space.”
Beaumont RCSI Cancer Centre is committed to providing the best cancer service to patients by combining first class clinical care with ground-breaking research and high-quality education and training. The Cancer Centre is made up of Beaumont Hospital, the Royal College of Surgeons in Ireland (RCSI) and St. Luke’s Radiation Oncology Network. Its mission is to provide equitable, individualised quality care to patients with cancer in north Dublin, the north east of Ireland and nationally.
Beaumont RCSI Cancer Centre is delighted to announce the success of the MSCA Postdoctoral Fellowship (Marie Skłodowska‑Curie Postdoctoral Fellow 2025) application led by Professor Robbie Woods, with Dr. Antara Sengupta as the incoming MSCAPF.
This highly competitive European fellowship supports outstanding early‑career researchers and enables them to develop their careers through world‑class training, mobility, and collaboration. The success of this proposal highlights the growing reputation of Beaumont RCSI Cancer Centre as a hub for impactful cancer research and international scientific excellence.
Dr. Sengupta’s fellowship will advance innovative research and contribute to supporting improved patient outcomes and strengthen the Centre’s translational research mission.
Professor Robbie Woods commented on the award:
“We are delighted to welcome Antara as part of our research team. Securing an MSCA Postdoctoral Fellowship is a major achievement, and we look forward to the important contributions her work will bring to our cancer research programme.”
This award reflects the Centre’s commitment to fostering scientific talent, building international partnerships, and driving research that makes a meaningful difference for cancer patients in Ireland and beyond.
We congratulate Dr. Antara Sengupta and Professor Robbie Woods on this significant accomplishment and look forward to supporting the next stages of this exciting research.
Cancer Snapshot Series.
Listen to Professor James Paul O’Neill, Consultant Otolaryngologist, Head and Neck Surgeon discuss the importance of HPV vaccination, and preventing multiple types of Cancer.
#HPVAwarenessDay #BRCC #CancerPrevention
Congratulations to Dr Anne-Marie Baird and Mr Seamus Cotter for winning the Public and Patient Partnership Award at the the Irish Cancer Society‘s Research Awards last week-Thursday Feb 18th. Embedded within the Lung Health Check Steering Committee, Dr Baird and Mr Cotter served as PPI partners ensuring that the realities and concerns of people impacted by lung cancer were heard at every stage of the research development as well as leading on community engagement events.
Mr Cotter currently chairs of the Irish Lung Cancer Community (ILCC), a united voice for people impacted by lung cancer, and Dr Baird is the immediate past president of Lung Cancer Europe (2020-2025) (LuCE).
The Irish Cancer Society Research Awards recognise the outstanding contributions made by researchers, support staff, and patient partners who drive cancer research forward in Ireland. Each year, these awards showcase innovative projects that improve our understanding of cancer, advance treatment options, and strengthen partnerships with patients and the public.
The Lung Health Check pilot, led by Beaumont RCSI Cancer Centre and funded by the Irish Cancer Society and EU4Health SOLACE was launched last year, invites high-risk individuals from specific Centric Health GP practices in North Dublin and the North-East region to attend a lung health check at a mobile scanning unit.
These awards demonstrate the incredible progress being made in cancer research and celebrate the dedication of Ireland’s research community and cancer care.
On 15-16 January, RCSI will host an exciting Regional Networking Event in its capacity as a Leading Cancer Centre within the INTERACT-EUROPE-100 education consortium. Building on an earlier EU-funded initiative co-chaired by RCSI past president Prof. Niall O’Higgins, the EU-co-funded INTERACT-EUROPE-100 project is a flagship initiative of Europe’s Beating Cancer Plan to provide new standards in teamwork in every cancer centre in Europe.
Cancer patients in Europe are treated by an array of different specialties and professions: medical oncologists, radiation oncologists, surgical oncologists, cancer nurses and many others. For cancer care to be delivered optimally, close collaboration among these professionals is essential. But that requires a thorough knowledge of each other’s roles and goals in treating any patient. The INTERACT-EUROPE-100 project allows various professional specialties across Europe to train together, improving collaboration and patient care through the implementation of an innovative Inter-Specialty Cancer Training Programme.
INTERACT-EUROPE 100 has a clear and unwavering objective: improve cancer care by improving the collaboration of those providing it. The INTERACT-EUROPE vision is all about breaking down medical silos. It provides professionals from different specialties with the skills to communicate with each other more effectively for better patient care.
The Regional Networking Event in Dublin will bring together around 40 participants representing medical oncology, surgery, cancer nursing, radiation oncology, pathology, and health & social care professionals from cancer centres in Austria, Belgium, Cyprus, Finland, France, Germany, Hungary, Italy, Lithuania, Slovakia, Slovenia, Sweden and Ireland! Participants will reflect on how the Inter-Specialty Cancer Training Programme is being implemented in their own centres, share best practices, and take part in workshops to strengthen multidisciplinary collaboration. All this with a healthy dose of RCSI hospitality and Irish culture – participants are sure to remember the ceili dance being hosted in RCSI’s new building 118 St. Stephen’s Green!
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.
On 15-16 January, RCSI will host an exciting Regional Networking Event in its capacity as a Leading Cancer Centre within the INTERACT-EUROPE-100 education consortium. Building on an earlier EU-funded initiative co-chaired by RCSI past president Prof. Niall O’Higgins, the EU-co-funded INTERACT-EUROPE-100 project is a flagship initiative of Europe’s Beating Cancer Plan to provide new standards in teamwork in every cancer centre in Europe.
Cancer patients in Europe are treated by an array of different specialties and professions: medical oncologists, radiation oncologists, surgical oncologists, cancer nurses and many others. For cancer care to be delivered optimally, close collaboration among these professionals is essential. But that requires a thorough knowledge of each other’s roles and goals in treating any patient. The INTERACT-EUROPE-100 project allows various professional specialties across Europe to train together, improving collaboration and patient care through the implementation of an innovative Inter-Specialty Cancer Training Programme.
INTERACT-EUROPE 100 has a clear and unwavering objective: improve cancer care by improving the collaboration of those providing it. The INTERACT-EUROPE vision is all about breaking down medical silos. It provides professionals from different specialties with the skills to communicate with each other more effectively for better patient care.
The Regional Networking Event in Dublin will bring together around 40 participants representing medical oncology, surgery, cancer nursing, radiation oncology, pathology, and health & social care professionals from cancer centres in Austria, Belgium, Cyprus, Finland, France, Germany, Hungary, Italy, Lithuania, Slovakia, Slovenia, Sweden and Ireland! Participants will reflect on how the Inter-Specialty Cancer Training Programme is being implemented in their own centres, share best practices, and take part in workshops to strengthen multidisciplinary collaboration. All this with a healthy dose of RCSI hospitality and Irish culture – participants are sure to remember the ceili dance being hosted in RCSI’s new building 118 St. Stephen’s Green!
We are delighted to confirm Professor Jarlath Bolger, Consultant Upper GI Cancer Surgeon and Ms. Caitriona Higgins, CNM III Cancer Directorate are our speakers at January’s Lunch & Learn “Bitesized Briefing On Cancer”.
Prof. Bolger will present of the impact of Exercise in Oesophageal Cancer and Caitriona will share an update on the Cancer Patient Partnership Working Group.
All staff are welcome and we hope to see you in the Richard Carmichael Lecture Theatre at 12.30 on the 11th February. Refreshments available afterwards.
Dr O’Reilly is clinical research fellow in the Beaumont RCSI Cancer Centre, with an interest in the development of novel liquid biopsy approaches in order to improve outcomes for patients with lung cancer.
David’s work on “Exhaled breath condensate tumour DNA analysis to predict progression on chemo-immunotherapy for patients with advanced non-small cell lung cancer” was selected from a prestigious group of global submissions and demonstrates a continued commitment to cancer research and progressing outcomes for patients with cancer.
This research is follows-on from research conducted as part of his PhD. During his PhD, the investigator led the ‘BRAND’ study, which investigated using exhaled breath samples to predict clinical benefit from treatment. The aim of his ASCO YIA award is specifically to investigate if exhaled breath liquid biopsy can be used to predict early progression on chemo-immunotherapy for patients with advanced non-small cell lung cancer.
The Conquer Cancer Young Investigator Award (YIA) aims to encourage and promote quality research in clinical oncology. Applicants are reviewed and evaluated by an independent selection committee. David is the only recipient of the award outside of North America this year.
Prof. Jarushka Naidoo, Professor of Medical Oncology here in Beaumont RCSI Cancer Centre, and research mentor to Dr. O’Reilly had this to say “Dr O’Reilly has received a very prestigious award from our foremost oncology society (ASCO- American society of clinical oncology), it’s Conquer Cancer Foundation Young Investigator Award. This is excellent news for Dr. O’Reilly and this is a real example of successful team science”.
As Ireland’s newly accredited European Cancer Centre, the Beaumont RCSI Cancer Centre, will hold its first conference in Dublin on Thursday, 22 September 2022.
The conference is the first of its kind to be held by the Centre, which is an innovative collaboration between Beaumont Hospital, RCSI University of Medicine and Health Sciences and St Luke’s Radiation Oncology Network.
The Beaumont RCSI Cancer Centre has recently been accredited by the OECI, Europe’s accreditation body for standards in cancer research, education and clinical care.
The inaugural cancer conference will bring together healthcare professionals, academics and key stakeholders to celebrate the accreditation and present the Cancer Centre’s vision for comprehensive cancer care in Ireland.
International key note speakers include Professor Alastair Thompson, Breast Cancer Surgeon and Professor and Chief, Section of Breast Surgery, Baylor College of Medicine and Dr Jean-Benoît Burrion, Chair of the OECI Accreditation and Designation Programme.
The Beaumont RCSI Cancer Centre is a partnership between Ireland’s leading healthcare professionals, academics, biologists, epidemiologists and statisticians across the disciplines of medicine, radiation, surgery and palliative care. The Centre specialises in the treatment of a wide range of cancers including breast, colorectal, lung, endocrine, head & neck, neuro oncology, urology, skin, haematology and upper gastro intestinal.
Commenting on the significance of the event, Professor Patrick Morris, Medical Director of the Beaumont RCSI Cancer Centre said: “The establishment of the Beaumont RCSI Cancer Centre formalises the alliance and commitment to cancer care that has long existed between the three partners involved, combining our expertise to create a centre of excellence with the scale and breadth to drive improvements nationally and through our international networks.”
Professor Leonie Young, Scientific Director of the Beaumont RCSI Cancer Centre, said: “A key goal of Beaumont RCSI Cancer Centre is to integrate world-class research and clinical education into the treatment of patients across all types of cancer. This conference is an important part of this strategy and will be of interest to the vast number of people who have been affected by cancer and their families as well as everyone in involved in the research and treatment of all forms of cancer in Ireland and worldwide.’
For further information on how to register and submit abstracts visit the conference webpage
